From: Research progress on non-protein-targeted drugs for cancer therapy
Intervention | Cancer | ClinicalTrials. gov Identifier | Current status |
---|---|---|---|
DC vaccine | Breast cancer, malignant melanoma | NCT00978913 | Phase I completed |
DC vaccine | AML | NCT01734304 | Phase I/II completed |
DC vaccine | Melanoma | NCT00940004 | Phase I/II completed |
DC vaccine with mRNA from tumor stem cells | GBM | NCT00846456 | Phase I/II completed |
mDC vaccine/ pDC vaccine | mCRPC | NCT02692976 | Phase II completed |
DC vaccine plus cisplatin | Melanoma | NCT02285413 | Phase II completed |
DC vaccine plus docetaxel | mCRPC | NCT01446731 | Phase II completed |
DC vaccine | AML | NCT05000801 | Recruiting |
DC vaccine plus temozolomide | GBM | NCT02649582 | Phase I/II recruiting |
DC vaccine plus temozolomide | High grade glioma, diffuse intrinsic pontine glioma | NCT04911621 | Phase I/II recruiting |
DC vaccine | AML | NCT01686334 | Phase II recruiting |
DC vaccine plus radiotherapy and IFN-α | Malignant melanoma | NCT01973322 | Phase II recruiting |
RNA-loaded DC vaccine plus basiliximab | Malignant neoplasms brain | NCT00626483 | Phase I completed |
TriMix-DC | Melanoma | NCT01066390 | Phase I completed |
TriMix-DC plus ipilimumab | Melanoma | NCT01302496 | Phase II completed |
TriMix | Breast cancer | NCT03788083 | Phase I recruiting |
BTSC mRNA-loaded DCs | GBM | NCT00890032 | Phase I completed |
CT7, MAGE-A3, and WT1 mRNA-electroporated LCs | Multiple myeloma | NCT01995708 | Phase I completed |
CEA-loaded DC vaccine | CRC | NCT00228189 | Phase I/II completed |
MiHA-loaded PD-L-silenced DC | Hematological malignancies | NCT02528682 | Phase I/II completed |
mRNA transfected DC | Androgen resistant metastatic prostate cancer | NCT01278914 | Phase I/II completed |
GRNVAC1 | AML | NCT00510133 | Phase II completed |
mRNA transfected DC plus docetaxel | Prostate cancer | NCT01446731 | Phase II completed |
Human CMV pp65-LAMP mRNA-pulsed autologous DCs | GBM | NCT02366728 | Phase II completed |
Human CMV pp65-LAMP mRNA-pulsed autologous DCs with or without varlilumab | GBM | NCT03688178 | Phase II recruiting |
pp65-shLAMP DC with GM-CSF/ pp65-flLAMP DC with GM-CSF | GBM | NCT02465268 | Phase II recruiting |
Autologous DCs loaded with autologous tumor RNA | Uveal melanoma | NCT01983748 | Phase III recruiting |
CV9103 | HRPC | NCT00831467 | Phase I/II completed |
CV9103 | HRPC | NCT00906243 | Phase I/II Terminated (Study closed after completion of Phase I) |
CV9104 | Prostate Cancer | NCT01817738 | Phase I/II terminated (Follow up period after primary analysis was prematurely stopped because more mature data will not impact the study outcome) |
CV9104 | Prostate Cancer | NCT02140138 | Phase II terminated (Recruitment was terminated after enrolment of 35 instead of 36 evaluable patients for administrative reasons.) |
CV9201 | NSCLC | NCT00923312 | Phase I/II completed |
CV9202 and local radiation | NSCLC | NCT01915524 | Phase I terminated (Slow recruitment in stratum 3: enrolled only 2 instead of 8 pts. within predicted time) |
CV9202 plus durvalumab and tremelimumab | NSCLC | NCT03164772 | Phase I/II completed |
mRNA-5671/V941 with or without pembrolizumab | KRAS mutant advanced or metastatic NSCLC, CRC or pancreatic adenocarcinoma | NCT03948763 | Phase I completed |
mRNA-2416 plus durvalumab | Advanced malignancies | NCT03323398 | Phase I/II terminated (This study was halted prematurely because the efficacy endpoints were not met for either treatment arm.) |
mRNA-4157 plus Pembrolizumab | Melanoma | NCT03897881 | Phase II active, not recruiting |
mRNA-4157 plus pembrolizumab | Solid tumors | NCT03313778 | Phase I recruiting |
mRNA-2752 plus durvalumab | Advanced or metastatic solid tumor malignancies or lymphoma | NCT03739931 | Phase I recruiting |
mRNA-4359 plus pembrolizumab | Advanced solid tumors | NCT05533697 | Phase I/II recruiting |
mRNA RNA loaded lipid particles | GBM | NCT04573140 | Phase I recruiting |
OTX-2002 | HCC and other solid tumor types known for association with the MYC oncogene | NCT05497453 | Phase I/II recruiting |
BNT141 plus nab-paclitaxel and gemcitabine | Advanced unresectable or metastatic CLDN18.2-positive solid tumors | NCT04683939 | Phase I/II recruiting |
BNT113 | HPV16 + head and neck cancer | NCT03418480 | Phase I/II recruiting |
BNT113 plus pembrolizumab | Unresectable head and neck SCC | NCT04534205 | Phase II recruiting |
BNT111 | Melanoma | NCT02410733 | Phase I active, not recruiting |
BNT111 plus cemiplimab | Unresectable Stage III or IV melanoma | NCT04526899 | Phase II recruiting |
Stabilized tumor-mRNA plus GM-CSF | Malignant melanoma | NCT00204607 | Phase I/II completed |
mRNA coding for melanoma associated antigens plus GM-CSF | Malignant melanoma | NCT00204516 | Phase I/II completed |
Personalized cellular vaccine | Brain cancer | NCT02808416 | Phase I completed |
Neoantigen tumor vaccine with or without PD-1/L1 | Advanced gastric cancer, esophageal cancer, and liver cancer | NCT05192460 | Recruiting |
Neoantigen mRNA personalised cancer SW1115C3 | Advanced malignant solid tumors | NCT05198752 | Phase I recruiting |
RO7198457 with or without atezolizumab | Advanced or metastatic tumors | NCT03289962 | Phase I active, not recruiting |
RO7198457 plus atezolizumab and mFOLFIRINOX | Pancreatic cancer | NCT04161755 | Phase I active, not recruiting |
RO7198457 plus pembrolizumab | Advanced melanoma | NCT03815058 | Phase II active, not recruiting |
RO7198457 | Stage II and stage III colorectal cancer | NCT04486378 | Phase II recruiting |
HB-201 | HPV 16 + confirmed oropharynx cancer, cervical cancer | NCT04630353 | Early Phase 1 recruiting |
GRANITE (GRT-C901/GRT-R902) | Colon cancer | NCT05456165 | Phase II recruiting |